International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.
about
Interferon for interferon nonresponding and relapsing patients with chronic hepatitis CResponse Prediction and Treatment Tailoring for Chronic Hepatitis C Virus Genotype 1 InfectionImpact of Hepatitis C Virus (HCV) Genotypes on Quantification of HCV RNA in Serum by COBAS AmpliPrep/COBAS TaqMan HCV Test, Abbott Antiretroviral Therapy HCV RealTime Assay, and VERSANT HCV RNA AssayBio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitisInduction versus noninduction antiviral therapy for chronic hepatitis C virus in patients with congenital coagulation disorders: a Canadian multicentre trialExpert opinion on the treatment of patients with chronic hepatitis COn-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formulaPredictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus controlSystemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis CIP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIVPersonalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized StudyEvaluated outcomes in patients with Chronic Hepatitis C.Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis BTreatment of hepatitis C virus infection: updated Swedish Consensus recommendations.Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled studyMeta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infectionSustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection.Optimal duration of treatment for HCV genotype 1 infection in slow responders: a meta-analysis.Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection.Review article: predicting response in hepatitis C virus therapy.Histamine dihydrochloride: actions and efficacy in the treatment of chronic hepatitis C infection.Improving anti-hepatitis C virus therapy.Sustained virologic response to peginterferon alpha-2a and ribavirin in 335 patients with chronic hepatitis C: a tertiary care center experience.Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.Combining longitudinal discriminant analysis and partial area under the ROC curve to predict non-response to treatment for hepatitis C virus.Host factors determining the efficacy of hepatitis C treatment.PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy--factors associated with advanced fibrosis.Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activityDifferences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis.Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy.The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.Are FoxP3(+) cells involved in hyporesponsiveness to interferon/ribavirin therapy in chronic hepatitis C?Design evaluation and optimization for models of hepatitis C viral dynamics.Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
P2860
Q24201588-B8B1D8E8-FD34-40BB-B4CA-90EA42AA9B4EQ27481003-FC5E364C-16AE-4F68-BE86-63611A36D012Q27481443-5466328F-1B23-4E40-A033-D679288E1110Q27488200-9B977FC6-48CD-4DE5-B49A-0D81E4AA3CEBQ27488232-4A9E038B-F8E3-4B63-A3DD-23AF1F930625Q27489903-70B51C99-C106-472E-8ED7-5FA1E5F395FAQ27490760-77F34FB6-CD15-4D48-B86F-37B253621BAFQ27490866-F5ABD955-8AB7-4919-8F9B-9A7E289C11CCQ28082128-F7FAC300-84D5-49BA-81C3-82A0C6443523Q28274298-6CC16971-68FB-487E-8079-301755F00D6AQ28287283-025E580B-978F-4C74-B01A-F828CC036F16Q28608449-8A7A6019-525A-4213-8B97-09C72F6A7F3CQ33596752-ED4D8D0A-FD95-45B7-9E79-677A0D64EB5CQ33842239-79142207-1829-4720-8184-F908CDD6F27FQ33918275-01FB221B-181C-4C81-B2DA-7E96223BA56EQ34087387-2CA8241A-5FBE-4E43-A849-74CCD78EDA0DQ34146792-6B6545E7-1C2E-422A-8640-15E1325E61E1Q34334776-C88173FA-E6F5-425A-997D-91A697A5F755Q34599847-651BB3A7-EE1A-40BD-94A4-437C22127EEDQ35007560-411E84E8-1A77-49F4-B3C7-EC13C22DBD91Q35205389-67290999-D388-4BB9-838A-FB30D070B366Q35582452-ABCD2CDB-CB0C-44DC-A611-8B48BC969BE8Q36346012-1AFD0BE9-0682-44C2-B6E3-81764FE50A4FQ36447562-A91F5629-EA7F-4E3A-980B-3219123A80CDQ36505483-7B5E5C78-F15A-4AD2-A05B-76195F1ED023Q36569749-D52A99BC-DBFC-4974-B25A-59F6E6156A4BQ37243555-0A00EA05-003D-4E9A-BBDE-A9A1D0EC9BC5Q37608271-971AE692-7FAC-485A-9CB1-17E064F83B46Q37702030-CEB287F7-1C02-4701-A98D-7ED4785939B0Q38056077-54941AF8-A06B-42C0-A5F0-8592DBE83F59Q38102776-46CF8FDF-BCE1-4FE7-A117-3BB045BB4F2DQ39739238-38E9DC59-7AA5-423A-A319-FB85B3A11847Q42227752-1EA7AC4D-D05C-482E-8260-46734C80AB7DQ42283286-C595BBF4-AD4F-4D49-AD72-BF2096ED1081Q42581407-37A1D892-A705-4E84-BB99-BC052EB8173AQ42725944-52E8A1A6-ED7B-4DB9-9309-D7A00D5035EDQ42981009-75293919-1F77-4E72-8FD4-349780E2F1C8Q42995153-49F735A2-E0AD-4B9D-B8AE-77CC14BA5C30Q43034515-A2BAB198-0DC3-4744-B5F2-788F2256189BQ43035013-6FE34520-32F4-4B6F-B469-84566CDDF282
P2860
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
International, multicenter, ra ...... ents with chronic hepatitis C.
@en
International, multicenter, ra ...... ents with chronic hepatitis C.
@nl
type
label
International, multicenter, ra ...... ents with chronic hepatitis C.
@en
International, multicenter, ra ...... ents with chronic hepatitis C.
@nl
prefLabel
International, multicenter, ra ...... ents with chronic hepatitis C.
@en
International, multicenter, ra ...... ents with chronic hepatitis C.
@nl
P2093
P50
P1476
International, multicenter, ra ...... ents with chronic hepatitis C.
@en
P2093
Alexandre Soulier
Avidan U Neumann
Christophe Hezode
DITTO-HCV Study Group
Elia Gianfranco
Elke Verheij-Hart
Esther Lukasiewicz
Francesco Negro
Ioannis Goulis
Jan-Maarten Vrolijk
P304
P356
10.1016/J.JHEP.2005.05.016
P50
P577
2005-08-01T00:00:00Z